We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+12.44%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.23B
AUM Growth
-$53.5M
Cap. Flow
-$116M
Cap. Flow %
-9.36%
Top 10 Hldgs %
73.9%
Holding
25
New
1
Increased
3
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$22.4M
2
CRM icon
Salesforce
CRM
+$13.1M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.74M
4
BBOT
BridgeBio Oncology
BBOT
+$2.41M

Top Sells

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$52.6M
2
INSM icon
Insmed
INSM
+$34.8M
3
ASML icon
ASML
ASML
+$26M
4
VALN
Valneva
VALN
+$12.2M
5
VRDN icon
Viridian Therapeutics
VRDN
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 69.46%
2 Technology 16.25%
3 Financials 11.46%
4 Consumer Discretionary 2.62%
5 Industrials 0.21%

No holdings matched the selected filter criteria.

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q1 2026 Portfolio in Review

As of Q1 2026, Novo Holdings A/S held 25 positions worth $1.23B, down 4.2% from $1.29B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Novo Holdings A/S withdrew a net $116M in Q1 2026, closing 3 positions and reducing 7 holdings. Its most notable exit was Zenas BioPharma, an estimated $52.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 68% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Xenon Pharmaceuticals worth $28.2M.

  • Novo Holdings A/S's largest Q1 2026 buy was Xenon Pharmaceuticals: 485,438 shares worth $28.2M.
  • Novo Holdings A/S added most to Salesforce in Q1 2026, an estimated $13.1M increase.
  • Novo Holdings A/S's biggest Q1 2026 reduction was ASML, cutting an estimated $26M.
  • Novo Holdings A/S fully exited Zenas BioPharma in Q1 2026, selling an estimated $52.6M.
  • Novo Holdings A/S's ten largest holdings make up 74% of its $1.23B portfolio in Q1 2026.
  • Novo Holdings A/S opened 1 new position and closed 3 in Q1 2026.
  • Novo Holdings A/S's portfolio value fell 4.2% quarter-over-quarter to $1.23B.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.